– CNBC
Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $13
Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $17 to $13.
Related Posts
Catalyst Pharmaceuticals Comments On FDA’s Announcement Of Its Position On Orphan Drug Exclusivity In Light Of The 11th Circuit Decision In Catalyst Pharmaceuticals, Inc. v. Becerra
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE®
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a
W W Grainger Shares Soar On Solid Q2, Raised FY22 Guidance
W W Grainger Inc (NYSE:GWW) reported second-quarter FY22 sales grew 19.6% year-over-year to $3.84 billion, +22% on a daily, constant…
What’s Happening With Applied Materials Stock?
Applied Materials, Inc. (NASDAQ: AMAT) shares are trading lower by roughly 4% to $140.22 over the trailing five sessions amid recent volatility in semiconductor and chip stocks.